Aventis submits additional Ketek information
Aventis submits additional analysis of clinical studies and postmarketing surveillance data in response to FDA's Jan. 24 "approvable" letter for antibiotic Ketek (telithromycin). The company filed additional safety data in 2002 following a June 2001 "approvable" letter (1"The Pink Sheet" Nov. 4, 2002, p. 16)...
You may also be interested in...
FDA's Anti-Infective Drugs Advisory Committee will review the safety profile of Aventis' Ketek (telithromycin) on Jan. 8, Exec VP-Commercial Operations Thierry Soursac told an investor conference call Oct. 29
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.